What question did this study set out to answer?

May 2, 2026

Consideration of Enrollment Rates of Asian, Asian Pacific Islander, and Hispanic Patients in Non-small Cell Lung Cancer Trials.

VNVinay Nittur CPC H ParkUniversity of California, Irvine MNMisako NagasakaSt. Marianna University School of Medicine

Key Points

The aim is to address the underrepresentation of Asian, Asian Pacific Islander, and Hispanic patients in non-small cell lung cancer trials and identify barriers to enrollment.
Discussed barriers to enrollment of diverse populations in clinical trials.
Outlined strategies for improving representation in trials for NSCLC.
Provided insights into the implications of enhanced diversity for clinical outcomes.
Identified key barriers affecting enrollment rates of minority groups.
Proposed actionable strategies to improve diversity in clinical trials.
Emphasized the importance of diverse representation for more inclusive clinical outcomes.

Abstract

Despite efforts over the last decade by clinical investigators and organizations to enhance diversity in clinical trials, significant underrepresentation of Asian, Asian Pacific Islander, and Hispanic patients remains an issue. Our editorial highlights key barriers to achieving equity in clinical trial enrollment among patients with non-small cell lung cancer (NSCLC) along with strategies to improve diversity to ensure more generalized clinical outcomes.

Perguntar à IA

Bookmark

View Full Paper